Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/32281
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gokengin, Deniz | en_US |
dc.contributor.author | Bursa, Dominik | en_US |
dc.contributor.author | Skrzat-Klapaczynska, Agata | en_US |
dc.contributor.author | Alexiev, Ivailo | en_US |
dc.contributor.author | Arsikj, Elena | en_US |
dc.contributor.author | Balayan, Tatevik | en_US |
dc.contributor.author | Begovac, Josip | en_US |
dc.contributor.author | Cicic, Alma | en_US |
dc.contributor.author | Dragovic, Gordana | en_US |
dc.contributor.author | Harxhi, Arjan | en_US |
dc.contributor.author | Aimla, Kerstin | en_US |
dc.contributor.author | Lakatos, Botond | en_US |
dc.contributor.author | Matulionyte, Raimonda | en_US |
dc.contributor.author | Mulabdic, Velida | en_US |
dc.contributor.author | Oprea, Cristiana | en_US |
dc.contributor.author | Papadopoulos, Antonios | en_US |
dc.contributor.author | Rukhadze, Nino | en_US |
dc.contributor.author | Sedlacek, Dalibor | en_US |
dc.contributor.author | Sojak, Lubomir | en_US |
dc.contributor.author | Tomazic, Janez | en_US |
dc.contributor.author | Vassilenko, Anna | en_US |
dc.contributor.author | Vasylyev, Marta | en_US |
dc.contributor.author | Verhaz, Antonija | en_US |
dc.contributor.author | Yancheva, Nina | en_US |
dc.contributor.author | Yurin, Oleg | en_US |
dc.contributor.author | Kowalska, Justyna | en_US |
dc.date.accessioned | 2025-01-17T10:38:00Z | - |
dc.date.available | 2025-01-17T10:38:00Z | - |
dc.date.issued | 2023-01-04 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/32281 | - |
dc.description.abstract | With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1−80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI AG | en_US |
dc.relation.ispartof | Vaccines | en_US |
dc.subject | HIV | en_US |
dc.subject | pre-exposure prophylaxis | en_US |
dc.subject | post-exposure prophylaxis | en_US |
dc.subject | Central and Eastern Europe | en_US |
dc.title | PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3390/vaccines11010122 | - |
dc.identifier.url | https://www.mdpi.com/2076-393X/11/1/122/pdf | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 1 | - |
dc.identifier.fpage | 122 | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Files in This Item:
File | Size | Format | |
---|---|---|---|
PrEP_Scale-Up_and_PEP_in_Central_and_Eastern_Europ (1).pdf | 619.67 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.